Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Collaborators (272)

Shoulson I, Oakes D, Fahn S, Lang A, William Langston J, LeWitt P, Warren Olanow C, Penney JB, Arbor A, Tanner C, Kieburtz K, Koller W, Warren Olanow C, Rodnitzky R, Stephen Fink J, Growdon JH, Paulson G, Kurlan R, Friedman JH, Gancher S, Nutt J, Rajput AH, Bennett JB, Frederick Wooten G, LeWitt P, Goetz C, Tanner C, Shannon K, Suchowersky O, Brin MF, Bressman SB, Weiner WJ, Sanchez-Ramos J, Jankovic J, Penney JB, Lang A, Hoehn M, Tetrud J, David Grimes J, Pfeiffer R, Shults C, Thal L, Gauthier S, Golbe LI, Perlmutter JS, Moses H 3rd, Reich SG, Hurtig HI, Stern M, Barter R, Vetere-Overfield B, Gauger L, Malapira T, Dobson J, Atamian S, Tennis M, Cohen JB, Desclos G, Hoffman E, Graefe K, Burke C, Marcus A, Denio L, Huber S, Woike T, Zoog K, Mendell R, Dudte K, Behr J, Gardiner IF, Lannon M, Carter J, Northrup S, Kanigan B, Turk M, Landow E, Schlick P, Mistura K, Susan Carroll V, Thelen JA, Demong C, Winfield L, Moskowitz C, Ingenito A, Sheldon C, Cornelius L, Heiberg D, Dunne C, Brady J, Kierans C, Belle-Scantlebury L, Duff J, Weber H, Savioni D, Lewis P, Jerome Kutner S, Gray P, Glaeske C, Hofman R, Margaret Pay M, Salmon D, McFaul F, Amyot D, Bergen M, McGee-Minnich L, O'Donnell P, Ferrise S, Shallow K, Axtell C, Baker D, Casaceli C, Eberly S, McDermott M, Marshall F, Nobel R, Orme C, Pelusio RM, Plumb S, Rudolph A, Randolph H, Sotack J, Watts A, Seeberger L, Kumar R, Jog M, Horn C, Shannon K, Blasucci L, Leehey M, Derian T, Grimes D, Mortensen M, Haas K, Tuite P, Rolandelli S, Hermanowicz N, Niswonger S, Kurlan R, Gardiner I, Miyasaki J, Johnston L, Tetrud J, Friedman J, Fernandez H, Lannon M, Rodnitzky R, Dobson J, Evidente V, Lind M, Carter J, Andrews P, Panisset M, Hall J, Racette B, Deppen P, Jankovic J, Hunter C, Jennings D, Fussell B, Stavris K, Molho E, Wojcieszek J, Belden J, Zhang L, Wilson L, Campbell P, Tempkin T, Scott B, Field J, Subramanian T, Siderowf A, Colcher A, Maccarone H, Hauser R, Delaney D, Nemeth J, Savitt J, Biglan K, Gerstenhaber M, Sahay A, Dalvi A, Gartner M, Schwieterman D, Uitti R, Turk M, Rivest J, Soucy D, Wooten F, Rost-Ruffner E, Schwarzschild M, Tennis M, Sethi K, Hatch L, Didonato C, Pfeiffer R, Pfeiffer B, Feigin A, Ayan J, Shannon B, Simuni T, Williams K, Wolff M, Elmer L, Davis K, deMarcaida A, Thurlow S, Chouinard S, Poiffaut H, Shill H, Stacy M, Marlor L, Danielson J, Truong D, Vo J, Zweig R, Feldt R, Waters C, Figueroa A, Tam A, Pahwa R, Parsons A, Hui J, Wu A, Kawai C, Camicioli R, King P, Dalvi A, Kang UJ, Shaviers E, Harding-Clay B, Reich S, Shulman L, Dignon C, Dustin K, Mark M, Caputo D, Rajput A, Novak P, Thomas CA, Sutton J, Young J, Song D, Fontaine D, Bertoni JM, Peterson C, Blindauer K, Petit J, Manyam B, McNeil-Keller D, Whetteckey J, LeWitt P, DeAngelis M, Ranawaya R, Suchowersky O, Pantella C, Sudarsky L, Tarsy D, Paul L, Scollins L, Forrest Gordon M, Bressman S, DiRocco A, Boyar K, Bronte-Stewart H, Andrzejewski A, Podskalny G, Fogle M, Galvez-Jimenez N, Alvarez J, Harik S, Tabbal S, Patterson J.

Author information

  • 1Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada. connie.marras@utoronto.ca


The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the study was to identify prognostic factors for time to acquiring disability requiring dopaminergic therapy that are reproducible within 2 large prospectively followed cohorts. Potential prognostic factors were identified using data from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, and their reproducibility was examined using data from the Parkinson Research Examination of CEP-1347 trial (PRECEPT). In multivariable analyses of the DATATOP cohort, higher baseline Unified Parkinson's Disease Rating Scale (UPDRS) scores, full-time employment, a lesser smoking history, and onset on the left side were associated with a shorter time to disability requiring dopaminergic therapy. PRECEPT data confirmed the associations of higher baseline UPDRS scores and full-time employment with shorter time to requiring treatment. Any clinical trial using the end point of time to disability requiring dopaminergic therapy should ensure that groups are well balanced with respect to baseline UPDRS scores and the proportion of subjects employed full time and should consider including these variables as covariates in the statistical model for primary analysis of treatment effects. We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands.

Copyright © 2011 Movement Disorder Society.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk